Skyepharma to unveil strengthened CDMO offering at CPhI Worldwide

Saint-Quentin-Fallavier, France: – Oral dosage specialist Skyepharma Productions S.A.S. (Skyepharma) will return to the annual CPhI Worldwide Expo with an expanded range of product offerings and capabilities as a fully-formed contract development and manufacturing organisation.

At CPhI Worldwide Expo, Skyepharma will be communicating the significant changes that have taken place within the organisation over the past 12 months as well as outlining its strengthened capabilities to offer end-to-end services in the development, manufacturing and packaging of oral solid forms.

Expanded presence

This will be Skyepharma’s third time exhibiting at CPhI Worldwide and this year’s presence will be stronger than ever. Our Skyepharma team will be exhibiting and helping with customers queries at Booth 120F75 in Hall 12 of the Messe Frankfurt showground, as part of the ICSE outsourcing exhibition.

The stand will feature 360^° views of the Skyepharma production facility showcased on touchscreen tables. 19 Skyepharma’s colleagues will be on hand to answer any business development or technical question.

On November 5 Skyepharma will repeat its popular French wine & cheese reception, to be held on the stand on the afternoon of Day one.

Our President David Lescuyer, Pharmaceutical development and Manufacturing Director Frédéric Chécot and Business Development manager Florence Lemoult will take part in a televised interview in front of the booth, outlining our differentiated capabilities and unique value proposition.

Development case study

On Wednesday, 6 November Isabelle Bonnaventure, Analytical Development Manager, will present a 20min case study on “Analytical development and technico-regulatory all along pharmaceutical development and manufacturing” during the Pharma Insight Briefing conference.

“CPhI Worldwide is the most high-profile pharmaceutical event in the world where every market player attends… Ever since 2017, Skyepharma has been a featured exhibitor and our presence here keeps growing,” commented Florence Lemoult, Business Development Manager.

Team spirit

She said Skyepharma’s presence would not only be an opportunity to strengthen customer relationship, develop its network of contacts and raise brand awareness and visibility in the market place, but would also demonstrate the company’s recent evolution with new investments, resources and offers such as packaging, serialisation and aggregation.

“We have become a real CDMO with new emphasis on D for Development,” said Ms. Lemoult.

“This is also a great way to demonstrate our strong company culture and further strengthen our team spirit,” she added. At Skypharma we have increased our communications efforts to gain more “share of voice” within the CDMO market. Marketing Communication Manager Perrine du Repaire, who has again led preparations for this event, said Skyepharma’s pre-expo communications have been far-reaching, including social media posts and videos and an email campaign targeting all visitors we met at previous expos.

Skyepharma has also set up a specific weblink to pre-book meetings in Frankfurt (see Resources).

About Skyepharma Production

Skyepharma Production S.A.S. (Skyepharma) is a specialist CDMO with particular expertise and capabilities in oral solid dosage forms, being a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech, premium food supplement and consumer health industries.

Skyepharma is the oral business unit of the Vectura Group of companies, an international leader in inhalation and other drug delivery forms.

As an integrated CDMO, the company’s vision is to help solve healthcare industry complexity with a mission to provide a dedicated and results-oriented team to deliver advanced oral dosage services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships. All of this is summed up in its strapline: ‘Expert and Agile CDMO partner for tailor-made solutions’.

The Skyepharma CDMO offer in solid oral dosage formats encompasses the whole value chain, including Formulation Development & Process Design, Analytical Development, Scale-up, Manufacturing, Packaging, Serialisation and Aggregation.

Skyepharma also provides a range of support services that help client companies from early stage development (up to clinical phases and registration), through scale-up and full commercial manufacturing and packaging to market introduction, including controlled substance handling, QbD methodology (FMEA, FTA, DOE), Troubleshooting, regulatory services, validation, registration and warehousing services.

About CPhI Worldwide 2019

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators and gain insights on latest industry trends.

Now in its 30^th year, the 2019 expo is a three-day event opening November 5 at the Messe showground in Frankfurt-am-Main, Germany, which last hosted CPhI in 2017.

CPhI Worldwide 2019 includes the co-located zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and events and the new BioProduction conference focusing on bioprocessing and manufacturing.

Together, they are expected to attract 45,000 delegates along with more than 2,500 exhibiting companies from some 160 countries.

The CPhI series is staged by leading Global B2B Events Organiser and Publisher UBM Live More information at: https://www.cphi.com/europe/

Resources

Click on Preview for more on Skyepharma at ICSE 2019.
Click on Skyepharma at ICSE 2019 for stand details.
Click on Meet Skyepharma to pre-book face to face meeting at CPhI Frankfurt.